Pharmacogenetics: Opportunities and Challenges for Health Innovation [electronic resource] /
Organisation for Economic Co-operation and Development.
Organisation for Economic Co-operation and Development.Secretary-General.
Paris : OECD Publishing,
2009.
Pharmacogenetics helps us understand the relationship between an individual's genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using  pharmacogenetics to improve the use of existing  medicines. Governments and others need to align regulatory, reimbursement and other incentives and work  with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.
Description based upon print version of record.
Includes bibliographical references.
Conclusions -- Business Models for Pharmacogenetics -- Regulatory Authorities and Reimbursement Mechanisms -- Physician and Patient Demand for Pharmacogenetics -- The Supporting Infrastructures for Pharmacogenetics -- Introduction to the Policy issues -- Pharmacogenetics and Drug Development -- Acronyms -- Executive Summary.
Pharmacogenetics helps us understand the relationship between an individual's genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using  pharmacogenetics to improve the use of existing  medicines. Governments and others need to align regulatory, reimbursement and other incentives and work  with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.
Pharmaceutical industry
Pharmacogenetics.